Mayflower Financial Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$790K Buy
6,254
+122
+2% +$16.1K 0.07% 223
2026
Q1
$855K Buy
6,132
+1,810
+42% +$253K 0.1% 187
2025
Q4
$530K Buy
4,322
+408
+10% +$49.6K 0.06% 241
2025
Q3
$435K Buy
3,914
+301
+8% +$34.2K 0.05% 273
2025
Q2
$401K Sell
3,613
-63
-2% -$6.71K 0.06% 269
2025
Q1
$412K Buy
3,676
+249
+7% +$25.7K 0.06% 257
2024
Q4
$317K Buy
+3,427
New +$309K 0.05% 289
2022
Q4
Sell
-4,767
Closed -$294K 356
2022
Q3
$294K Buy
4,767
+73
+2% +$4.6K 0.05% 253
2022
Q2
$290K Sell
4,694
-58
-1% -$3.59K 0.04% 253
2022
Q1
$283K Sell
4,752
-878
-16% -$56.1K 0.04% 283
2021
Q4
$409K Buy
5,630
+74
+1% +$5.1K 0.05% 219
2021
Q3
$372K Sell
5,556
-482
-8% -$33.9K 0.05% 228
2021
Q2
$416K Buy
6,038
+3
+0% +$200 0.06% 196
2021
Q1
$390K Sell
6,035
-6
-0.1% -$387 0.06% 192
2020
Q4
$352K Buy
+6,041
New +$365K 0.06% 179

Other funds holding GILD

Mayflower Financial Advisors's GILD Position: Q2 2026 in Review

Mayflower Financial Advisors increased its Gilead Sciences (GILD) stake by 2% in Q2 2026, buying an estimated $16.1K and bringing the position to 6,254 shares worth $790K. The position accounts for 0.07% of the portfolio, ranked #223.

Mayflower Financial Advisors first reported a position in GILD in Q4 2020 and has held it in 15 quarters since. The position peaked at $855K in Q1 2026. 849 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Mayflower Financial Advisors held 6,254 shares of Gilead Sciences worth $790K as of Q2 2026.
  • Mayflower Financial Advisors bought 122 Gilead Sciences shares in Q2 2026, an estimated $16.1K.
  • Gilead Sciences made up 0.07% of Mayflower Financial Advisors's portfolio in Q2 2026, its #223 holding.
  • Mayflower Financial Advisors first reported a position in Gilead Sciences in Q4 2020 and has held it in 15 quarters since.
  • Mayflower Financial Advisors's Gilead Sciences position peaked at $855K in Q1 2026.
  • 849 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Mayflower Financial Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.